Eli Lilly Announces Positive Phase 3 Results for Jaypirca Combination Therapy in Relapsed or Refractory CLL/SLL
Eli Lilly reported positive results from the Phase 3 BRUIN CLL-322 trial, showing that combining its drug pirtobrutinib (Jaypirca) with venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The results could support regulatory submissions to expand Jaypirca's use, potentially impacting the oncology drug market.
Tickers: $LLY